Leading Players in the Taiwan Dermatitis Market | Insights & Top Companies 2026

Q: How do global players like Sanofi and AbbVie maintain their lead in Taiwan?

Multinational giants maintain their lead by securing National Health Insurance reimbursement for high-cost biologics, and managing large-scale local clinical trials.

Q: What role do domestic players like Sinphar and OEP play in treatment?

Regional players are the major providers of accessible care, manufacturing high-quality topical corticosteroids and emollients that serve as a first-line defence.

Q: Which organization leads the biological therapy segment for atopic dermatitis in Taiwan?

Sanofi Taiwan is the current leader, with its biological treatment being the first of its kind to be widely adopted for severe atopic dermatitis.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA12278

Publication Date: Apr 2026

Leading Players in the Taiwan Dermatitis Market

The Taiwan Dermatitis Market is driven by leading companies, each having a significant market share through advanced therapeutic drugs and clinical research for atopic dermatitis and eczema management. Key players in the market include Sanofi Taiwan, AbbVie Taiwan, Pfizer Taiwan, Eli Lilly Taiwan, Galderma Taiwan, LEO Pharma Taiwan, Astellas Pharma Taiwan, Orient EuroPharma (OEP), Sinphar Pharmaceutical, and TTY Biopharm.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Taiwan Dermatitis Market.

View Main Report Schedule Analyst Call

Taiwan Dermatitis Market Overview

According to 6Wresearch, the Taiwan dermatitis market is increasing rapidly due to the rising prevalence of allergic conditions and the growing adoption of targeted biological therapies. Dermatitis is recognized by the inflammation of the skin, leading to symptoms such as itching, redness, and scaling.

The rising occurrence of atopic dermatitis has led to an increasing demand for monoclonal antibodies and JAK inhibitors. The increased investment in healthcare infrastructure and the rising awareness of chronic skin conditions are further contributing to the growth of the market.

Competitive Landscape

The competitive landscape of the Taiwan Dermatitis Industry includes global pharmaceutical giants and innovative domestic firms, that offers the latest technology therapeutic tools required for the management of the disease. Industry leaders are engaged in the development and supply of topical corticosteroids, calcineurin inhibitors, and systemic biologics.

Below is the list of leading players in the Taiwan Dermatitis Market:

1. Sanofi Taiwan

Company Name	Sanofi Taiwan
Established Year	1983 (Incorporated locally)
Headquarters	Taipei, Taiwan
Official Website	Click Here

Sanofi is a global leader in immunology, driving the market with biological therapies, which has revolutionized the treatment of atopic dermatitis.

2. AbbVie Taiwan

Company Name	AbbVie Taiwan
Established Year	2013 (Spin-off)
Headquarters	Taipei, Taiwan
Official Website	Click Here

AbbVie specializes in advanced immunology, offering JAK inhibitors that provide rapid relief for patients with chronic dermatitis symptoms.

3. Pfizer Taiwan

Company Name	Pfizer Taiwan
Established Year	1962
Headquarters	New Taipei City, Taiwan
Official Website	Click Here

Pfizer is a dominant force, providing a diverse portfolio ranging from topical inhibitors to systemic JAK inhibitors.

4. Eli Lilly Taiwan

Company Name	Eli Lilly Taiwan
Established Year	1966
Headquarters	Taipei, Taiwan
Official Website	Click Here

Eli Lilly provides high-efficacy systemic treatments for inflammatory skin conditions, focusing on biologics that target the interleukin pathways.

5. Galderma Taiwan

Company Name	Galderma Taiwan
Established Year	2001 (Taiwan branch)
Headquarters	Taipei, Taiwan
Official Website	Click Here

Galderma is a pure-play dermatology company, offering prescription medicines and consumer dermo-cosmetics essential for long-term eczema management.

6. LEO Pharma Taiwan

Company Name	LEO Pharma Taiwan
Established Year	2010 (Local entity)
Headquarters	Taipei, Taiwan
Official Website	Click Here

LEO Pharma focuses exclusively on medical dermatology, providing gold-standard topical treatments for chronic skin inflammation.

7. Astellas Pharma Taiwan

Company Name	Astellas Pharma Taiwan
Established Year	2005 (Merger)
Headquarters	Taipei, Taiwan
Official Website	Click Here

Astellas is a key provider of non-steroidal topical calcineurin inhibitors, which are vital for patients requiring steroid-free maintenance.

8. Orient EuroPharma (OEP)

Company Name	Orient EuroPharma (OEP)
Established Year	1982
Headquarters	Taipei, Taiwan
Official Website	Click Here

OEP is a leading firm that develops a wide range of dermatological products, bridging the gap between local manufacturing and global partnerships.

9. Sinphar Pharmaceutical

Company Name	Sinphar Pharmaceutical
Established Year	1977
Headquarters	Yilan County, Taiwan
Official Website	Click Here

Sinphar is a major local manufacturer specializing in ointments and creams, widely used across clinics for the management of dermatitis.

10. Menarini Taiwan

Company Name	Menarini Taiwan
Established Year	2011 (Following Invida acquisition)
Headquarters	Taipei, Taiwan
Official Website	Click Here

Menarini provides specialized dermatological solutions and barrier repair therapies that are essential for restoring skin health in dermatitis patients.